Plus Therapeutics (PSTV)
(Delayed Data from NSDQ)
$1.69 USD
-0.07 (-4.17%)
Updated Apr 18, 2024 03:57 PM ET
After-Market: $1.76 +0.07 (4.06%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum A VGM
Income Statements
Fiscal Year end for Plus Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 5 | 0 | 0 | 0 | 7 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 5 | 0 | 0 | 0 | 7 |
Selling & Adminstrative & Depr. & Amort Expenses | 18 | 20 | 12 | 10 | 11 |
Income After Depreciation & Amortization | -13 | -20 | -12 | -10 | -4 |
Non-Operating Income | 0 | 0 | 0 | 2 | 2 |
Interest Expense | 0 | 1 | 1 | 1 | 2 |
Pretax Income | -13 | -20 | -13 | -8 | -3 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -13 | -20 | -13 | -8 | -3 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | -8 |
Net Income (GAAP) | -13 | -20 | -13 | -8 | -11 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -13 | -19 | -12 | -9 | -2 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -13 | -20 | -12 | -10 | -4 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 3.14 | 0.12 | 0.05 | 0.02 | 0.01 |
Diluted EPS Before Non-Recurring Items | -4.24 | -173.08 | -249.50 | -418.08 | -622.63 |
Diluted Net EPS (GAAP) | -4.24 | -11.54 | -16.64 | -27.89 | -123.99 |
Fiscal Year end for Plus Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 1.31 | 1.24 | 1.85 | 0.51 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 1.31 | 1.24 | 1.85 | 0.51 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 5.17 | 4.49 | 3.34 | 5.23 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.86 | -3.25 | -1.49 | -4.72 |
Non-Operating Income | NA | 0.11 | 0.12 | 0.12 | 0.05 |
Interest Expense | NA | 0.06 | 0.09 | 0.11 | 0.13 |
Pretax Income | NA | -3.81 | -3.22 | -1.48 | -4.81 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -3.81 | -3.22 | -1.48 | -4.81 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -3.81 | -3.22 | -1.48 | -4.81 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 5.44 | 3.23 | 2.51 | 0.16 |
Diluted EPS Before Non-Recurring Items | NA | -0.70 | -1.00 | -0.59 | -31.47 |
Diluted Net EPS (GAAP) | NA | -0.55 | -1.00 | -0.59 | -2.10 |